Dr. Lal PathLabs Limited EBIT

Dr. Lal PathLabs Limited (LALPATHLAB.NS) currently reports a EBIT of $7.4B as of June 2026. That compares with $6.8B in the prior-year period — up 9.5% year over year. That is below the sector sector average of $2.6T. Use the charts on this page to explore Dr. Lal PathLabs Limited's EBIT history and peer comparisons.

Dr. Lal PathLabs Limited's EBIT increased from $6.8B to $7.4B — a 9.5% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Dr. Lal PathLabs Limited's EBIT of $7.4B is lower than the its sector sector average of $2.6T. That is roughly 99.7% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Dr. Lal PathLabs Limited reported $7.4B in EBIT as of June 2026. That compares with $6.8B in the prior-year period — up 9.5% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $7.4B, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is $2.6T. From there, open related valuation or income-statement pages for Dr. Lal PathLabs Limited, and consider following LALPATHLAB.NS for alerts when major investors trade the stock.